How we think about cardiovascular risk has changed a lot. We used to focus on 総コレステロール総コレステロールは、悪玉も善玉も含め、すべての粒子に含まれるコレステロールの合計です。. and later LDLコレステロールLDLコレステロール（LDL-C）は、LDL粒子内に存在するコレステロールの量です。これは、ほとんどすべての標準的な検査報告書に記載されている数値です。. (LDL-C) as the main villains. Now, the picture is more precise: risk is driven by how many 動脈硬化惹起性粒子動脈硬化惹起性粒子とは、LDL、IDL、VLDL、リポ蛋白(a)といったアポB含有リポ蛋白のことであり、動脈壁に侵入・停滞してプラークの成長を開始・持続させます。本論文では、プラークの退縮を達成するために大幅かつ持続的に低下させなければならない対象を指す言葉としてこの用語を使用しています。. are circulating, which genetically “high-risk” particles are present, and how much 炎症炎症は、怪我や侵入物とみなしたものに対する免疫システムの反応です。これにより腫れや熱、そして浄化細胞がもたらされます。. is active in the vessel wall. At the heart of this newer view is a practical triad of バイオマーカーバイオマーカーとは、健康や病気の状態について教えてくれる、体内で測定可能なもののことであり、例えば、検査値、スキャン画像の結果、血圧の数値などが挙げられます。.: アポリポ蛋白アポリポ蛋白とは、血液中の脂肪を運ぶ粒子に結合しているタンパク質です。脂肪と水は混ざらないため、これらのタンパク質は脂肪が血流の中を安全に移動できるようにする包みのような役割を果たします。. B-100 (アポリポ蛋白BアポBは、動脈の壁に詰まってプラークを引き起こす可能性のあるコレステロール粒子のすべての外側に存在するタンパク質です。それらの粒子はそれぞれ、正確に1個のアポBを運んでいます。.), which counts the number of atherogenic リポタンパク質リポタンパク質とは、脂肪とコレステロールを血流に乗せて運ぶ小さなカプセルのことです。脂肪は水に溶けないため、移動するにはタンパク質の包みが必要です。. particles;¹ リポ蛋白(a)リポタンパク(a)（Lp(a)と表記され、「L-P-リトル-a」と発音される）は、余分な粘着性のあるタンパク質が付着したLDL様粒子です。. [Lp(a)], a mostly inherited LDL-like particle with added thrombotic risk;² and high-sensitivity C反応性タンパク質C反応性タンパク（CRP）は、体内のどこかで炎症が起きているときに肝臓が産生する物質です。この検査の高感度バージョンであるhs-CRPは、心疾患のリスクを評価するために使用されます。. (hsCRP), a marker that tracks systemic and vascular inflammation.³

LDL-C still matters and remains the standard therapeutic target, but clinical experience (and growing evidence) shows that LDL-C can miss important risk—especially when ApoB is high, Lp(a) is elevated, or hsCRP suggests ongoing inflammation.⁴ In many patients, these three factors stack together and create risk that feels “out of proportion” to traditional lipid panels. When you compare this biochemical and genetic risk profile with behavioral insults like cigarette 喫煙喫煙は血管の内壁を傷つけ、血圧を上げ、血液を凝固しやすくし、プラークの成長を早めます。., the hierarchy of risk becomes even more nuanced, reinforcing the need for personalized prevention strategies in both primary and 二次予防二次予防とは、すでに心臓発作、脳卒中、またはステント治療を経験した患者に対して、次の発作を防ぐために治療を行うことです。..⁵

The Molecular Framework of Apolipoprotein B-100 and Particle Pathogenicity

動脈硬化症動脈硬化は、ほとんど的心筋梗塞と多くの脳卒中の背景にある病気です。コレステロールの粒子が動脈の壁に入り込み、体がそれを掃除するために免疫細胞を送り込み、何年もかけてその堆積物が硬化してプラークになります。. doesn’t start because the blood contains “too much コレステロールコレステロールは、体が必要とするロウ状の物質です。細胞壁、ホルモン、ビタミンD、そして食べ物を消化する胆汁の材料となります。コレステロールがなければ私たちは生きていけません。.” in the abstract. It starts because too many atherogenic particles are circulating, and a fraction of them get trapped in the 動脈動脈は、心臓から全身へ血液を送り出す血管です。. wall.⁶ The single best way to understand this is to think in terms of particle number, not just cholesterol mass.⁶

Apolipoprotein B (ApoB) is the key structural タンパク質タンパク質は、体内の筋肉や組織の構築と修復に使用される栄養素です。. on all potentially atherogenic lipoproteins: very-low-density lipoproteins (VLDLVLDL（超低密度リポ蛋白）は、肝臓が中性脂肪を体内の他の部位へと送り出すために作り出す粒子です。.）、中間密度リポタンパク質（IDLIDL（中等密度リポ蛋白）は、トリセリドを多く運ぶ大型の粒子が収縮してLDL粒子へと変化する過程の中間で形成される粒子です。.)、低密度リポタンパク質（LDLLDL（低密度リポ蛋白）は、コレステロールを血液中に運ぶ主要な粒子であり、動脈壁に詰まる主原因となるものです。.), and also lipoprotein(a).⁸ Each of these particles carries exactly one アポB-100ApoB-100 is the full-length form of apolipoprotein B found on LDL, VLDL, IDL, and remnant lipoproteins; its positively charged amino-acid domains bind ionically to negatively charged proteoglycan side chains in the arterial wall, physically trapping the particle in the intima and initiating plaque formation. molecule, which makes ApoB a convenient biological “counter”: the ApoB concentration in plasma tells you how many atherogenic particles are present.⁷

This is why relying exclusively on LDL-C can be misleading in some common clinical settings—especially hypertriglyceridemia, メタボリックシンドロームMetabolic syndrome is a cluster of five problems that tend to travel together: a large waist, high triglycerides, low HDL, high blood pressure, and high blood sugar. Having three or more counts., and type 2 糖尿病糖尿病は、体が十分なインスリンを作らないか、あるいは作られたインスリンに反応しなくなることで、血糖値が常に高すぎる状態になる疾患です。..⁶ In these states, LDL particles often carry less cholesterol per particle, shifting toward small, dense LDL (sdLDL). That means a patient can show an “acceptable” LDL-C value while still having a high number of LDL particles—a pattern often described as LDL-C/ApoB discordanceA clinical pattern in which a patient's measured LDL cholesterol mass appears acceptable while the ApoB particle count is elevated, indicating more atherogenic particles than the cholesterol number alone would suggest; common in metabolic syndrome and hypertriglyceridemia..⁹ ApoB measurement bypasses that limitation by directly reflecting 粒子負荷粒子負荷とは、血漿中を循環する動脈硬化性リポ蛋白粒子の総数のことであり、ApoBによって最もよく測定されます。これはコレステロール量とは区別されます。なぜなら、リポ蛋白が動脈壁に浸潤して捕捉される頻度を決定するのは、コレステロールの量ではなく、粒子の物理的な数だからです。., which better captures the likelihood of lipoprotein entry into the arterial 内膜内膜は動脈壁の一番内側の層であり、平滑な内壁のすぐ下に位置しています。..⁷

Mechanisms of Subendothelial Infiltration and Retention

Atherosclerosis begins when the 内皮内皮は、すべての血管の内側にある極めて薄く滑らかな裏地であり、厚さはわずか1細胞分です。.—normally a smooth barrier—becomes more permeable or dysfunctional, often due to shear stress, oxidative injury, metabolic dysfunction, or chemical exposure (including tobacco smoke).¹¹ Once that barrier is compromised, アポB含有リポ蛋白リポタンパク質（LDL、IDL、VLDLおよびそれらの残渣を含む）は、それぞれ表面に1分子のアポリポタンパク質Bを結合している。各粒子が動脈壁に捕捉される可能性があるため、コレステロールの質量そのものではなく、粒子数がアテローム性動脈硬化症の主要な要因となっている。. can move into the arterial intima.¹⁰

What matters next is not only entry, but retention. In the 内皮下腔内皮下腔は、動脈の内膜のすぐ下、1層の細胞とその下の筋肉の間にある狭い隙間である。., ApoB particles interact with the 細胞外マトリックスThe extracellular matrix is the scaffolding of collagen and other fibers that holds tissue together and gives an artery wall its strength. rather than simply drifting by concentration gradients.¹² ApoB-100 contains positively charged regions that bind to negatively charged sulfate groups on arterial proteoglycans. This electrostatic interaction is one of the reasons particles become “stuck” in the vessel wall—an essential early step in 歯垢プラークとは、動脈の壁の内側にコレステロール、免疫細胞、瘢痕組織、カルシウムが蓄積したものです。. formation.¹⁰ Once trapped, particles undergo oxidative and enzymatic modification, generating oxidized lipoproteins that are far more inflammatory and immunogenic than native particles.¹³

These modified particles act like danger signals. They recruit monocytes, promote マクロファージマクロファージは、ゴミや侵入者を飲み込む大きなどん欲な免疫細胞です。その名前は文字通り「大食い」を意味します。" uptake through scavenger receptors, and drive the formation of lipid-laden 泡沫細胞A foam cell is an immune cell that has eaten so much trapped cholesterol that it swells up and looks foamy under a microscope.—one of the earliest histologic hallmarks of atherosclerotic 病変循環器学において、病変とは冠動脈を狭窄させるアテローム性動脈硬化プラークの不連続な領域を指し、通常はそれが引き起こす内腔閉塞のパーセンテージによって記述される。この記事では、最も重要な病変が治療された後、血管径が小さすぎてステントを受け入れることができない4つの遺残病変について述べている。..¹³

Stoichiometry and Diagnostic Precision of ApoB

ApoB’s clinical advantage is not only conceptual—it’s practical. Much of routine LDL-C reporting still depends on calculated methods, most commonly the フリーデワルトの式A widely used mathematical formula that estimates LDL cholesterol from total cholesterol, HDL cholesterol, and triglycerides rather than measuring it directly; it becomes unreliable when triglycerides are elevated or blood is drawn in a non-fasting state, which is one reason ApoB measurement is considered more accurate in certain patients.:¹⁴

This approach becomes less accurate when 中性脂肪トリグリセリド（中性脂肪）は、血液中および体内の蓄積脂肪の主要な形態です。. are elevated (typically when TG exceed ~3.5–4 mmol/L) or when blood is drawn in a non-fasting state.¹⁴ ApoB, in contrast, is measured directly through immunoassays (immunoturbidimetric or immunonephelometric methods) that have been internationally standardized.¹⁵ In practice, ApoB tends to show lower analytic bias and better reproducibility than calculated lipid measures, which is why it is increasingly favored for assessing particle-driven risk.⁷

Physiological Metric	Diagnostic Method	Sensitivity to Fasting
LDL-C	Cholesterol mass	Calculation (Friedewald)
アポB-100	Particle count (1:1 ratio)	Direct measurement
非HDL-C	All atherogenic cholesterol	Calculation (TC − HDL-C)
Lp(a)	Genetic particle subtype	Immunoturbidimetric

Lipoprotein(a): The Genetic Vanguard of Atherothrombosis

Lp(a) is one of the most clinically important (and frustrating) lipoproteins because it is largely genetically determined and minimally affected by lifestyle changes. Structurally, Lp(a) looks like an LDL particle with an attached additional protein—apolipoprotein(a) [apo(a)]—linked to ApoB-100 by a disulfide bond.² It’s this additional apo(a) component that makes Lp(a) biologically distinctive and often more dangerous than standard LDL. Some estimates suggest it may be several-fold more potent as a driver of 心血管疾患心血管疾患とは、心臓発作、脳卒中、下肢の動脈閉塞など、心臓や血管に関する問題の総称です。. than LDL alone.¹⁶

Genetic Regulation and Kringle IV Complexity

Lp(a) levels are mainly controlled by the LPA geneLPA is the gene that determines how much lipoprotein(a) you make. Your version is fixed at conception. on chromosome 6q26–q27. Lp(a) concentration is typically 70% to 90% heritable and remains relatively stable over a lifetime, unlike LDL-C which can shift substantially with diet, 体重減少Weight loss means reducing body fat, whether through food changes, exercise, medication, or surgery., and medications.¹⁷ The striking variability in Lp(a) between individuals—sometimes over a 1000-fold range—comes largely from copy-number variation in the Kringle IV type 2 (KIV2) repeatsLooped protein domains within apolipoprotein(a) whose copy number varies widely between individuals; people with fewer KIV2 repeats produce smaller apo(a) isoforms and tend to have higher plasma Lp(a) concentrations, accounting for much of the inherited variability in Lp(a) levels. within apo(a).¹⁸

Kringle domains are looped structures stabilized by disulfide bonds. Apo(a) contains multiple kringle subtypes (KIV1–KIV10), but KIV2 is the one that varies widely across people. Those with fewer KIV2 repeats generally make smaller apo(a) isoforms and tend to have higher plasma Lp(a) levels. This inverse relationship between apo(a) size and Lp(a) concentration explains much of the genetic contribution to cardiovascular risk from Lp(a).¹⁹

The Dual Mechanisms of Lp(a) Pathogenicity

Lp(a) increases risk through two main pathways that overlap in real-world disease: a pro-atherogenic/pro-inflammatory pathway and a pro-thrombotic/anti-fibrinolytic pathway.²²

Atherogenic and pro-inflammatory drive: Like other ApoB particles, Lp(a) can cross the endothelium and accumulate in the intima. But Lp(a) is also a major carrier of oxidized phospholipids (OxPL) in plasma.²⁰ OxPL behave like strong inflammatory ligands, promoting endothelial activation, smooth muscle proliferation, macrophage dysfunction, and sometimes apoptosis—features that contribute to plaque growth and instability.²⁰

Thrombotic and anti-fibrinolytic interference: Apo(a) shares significant structural homology with プラスミノーゲン血栓を溶解する酵素であるプラスミンへと変換される血清タンパク質。Lp(a)中のアポ(a)はプラスミン原と強い構造的相同性を共有しており、これによりLp(a)は血栓の分解を競合的に阻害する。..²¹ Because of this resemblance, Lp(a) can compete with plasminogen for binding sites on fibrin, interfering with plasmin generation and impairing 線溶The physiological process by which the body dissolves blood clots through the enzyme plasmin; Lp(a) impairs this process by competing with plasminogen for fibrin-binding sites, reducing clot clearance and increasing the risk of an occlusive cardiac event..²² In effect, Lp(a) encourages thrombus persistence, increasing the chance that プラーク破裂Plaque rupture is when the protective cap over a plaque tears open, spilling its contents into the bloodstream. leads to a clinically significant occlusive event such as 心筋梗塞詳しい項目については心臓発作をご覧ください。..²²

Systemic Inflammation and the Sentinel Role of hsCRP

Atherosclerosis is now widely understood as a chronic inflammatory condition affecting the arterial wall.²³ Among the inflammatory biomarkers available clinically, hsCRP remains the most commonly used and best standardized.³ hsCRP does not tell you where inflammation is coming from, but persistent low-grade elevation strongly correlates with vascular inflammatory risk.³

The NLRP3 Inflammasome and CRP Induction

いつ cholesterol crystalsWhen cholesterol accumulates past what a plaque can hold in solution, it crystallizes into sharp needle-like structures. and oxidized ApoB particles build up in the intima, they activate immune pathways, including the NLRP3インフラマソームThe NLRP3 inflammasome is an intracellular protein complex in immune cells that, when activated by cholesterol crystals, oxidized lipids, or other danger signals within an atherosclerotic plaque, triggers the release of the inflammatory cytokines interleukin-1β and interleukin-6, accelerating plaque growth and instability. in macrophages.²⁴ This leads to processing of pro-interleukin-1β and pro-IL-18 into active cytokines.²⁴ These cytokines stimulate downstream IL-6Interleukin-6, or IL-6, is a signaling molecule the immune system uses to spread an inflammatory message through the body. signaling, which triggers the liver to synthesize and release CRP.²⁵

CRP can spike dramatically during infection, but chronically elevated hsCRP (often defined as hsCRP ≥ 2 mg/L) behaves more like a “smoke detector” for ongoing vascular inflammation and future cardiovascular events.³

Lessons from the JUPITER Trial

その JUPITER trialThe JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial enrolled individuals with 'normal' LDL-C but elevated hs-CRP and showed that rosuvastatin significantly reduced cardiovascular events in this population, demonstrating that inflammatory risk exists and is clinically significant even when conventional cholesterol metrics appear acc… was a turning point because it showed that inflammatory risk can identify high-risk patients even when LDL-C looks fine.²⁶ The study enrolled individuals with LDL-C below usual treatment thresholds (<130 mg/dL) but with hsCRP ≥2.0 mg/L. Participants receiving ロスバスタチンRosuvastatin, sold as Crestor, is the most potent statin available and stays largely in the liver rather than spreading through the body. 20 mg daily had a 44% reduction in major cardiovascular events.²⁶ Clinically, the takeaway was simple: some patients carry substantial risk through inflammation even when they do not appear “hyperlipidemic” by LDL-C alone.

Mapping the Interplay: Synergistic Risk and Pathogenic Cross-talk

ApoB, Lp(a), and hsCRP do not operate in isolation. Their relationship is better described as interactive, with overlapping mechanisms that can amplify each other’s harm.⁴

High ApoB means more particles enter the vessel wall and more substrate becomes available for oxidative modification. Those modified particles intensify inflammation, raising hsCRP. Inflammation then further disrupts 血管内皮機能血管の内側を覆う内膜が血管の緊張、炎症、血液凝固を調節する能力。健康な内視細胞は一酸化窒素を放出し、動脈をリラックスさせ、プラーク形成に対する抵抗力を保ちます。., making it easier for additional ApoB particles to enter—creating a self-reinforcing loop.²³

This synergy shows up clearly in large population studies. In a study of over 320,000 UKバイオバンクUK Biobank holds detailed genetic, lifestyle, and health data on half a million British volunteers, linked to their medical records. participants, LDL-C, Lp(a), and hsCRP were each independently associated with 主要心血管イベント主要心血管イベント、またはMACEとは、心血管死、心筋梗塞、脳卒中など、研究においてまとめて集計される有害な転帰のグループのことである。. (MACE), but the combined effect was far greater than any single marker alone.⁴

Biomarker Risk Strata	MACE Risk Elevation (Non-users of スタチンスタチンは、肝臓がコレステロールを作るのに使う酵素の働きを遅らせます。肝臓は血液中からより多くのコレステロールを取り除くことでこれに反応し、そこに真の利益があります。.)
全マーカー低値	1.00 (Reference)
High LDL-C Only	+13% risk per SD
High Lp(a) Only	+8% risk per SD
High hsCRP Only	+6% risk per SD
Triple Elevation	+77% risk (HR 1.77)

Comparison of Biomarker Risks to the Pathogenic Impact of Smoking

Smoking remains one of the most aggressive cardiovascular toxins because it generates 酸化ストレス酸化ストレスとは、有害な活性分子と、それらを中和する身体の能力との間の不均衡です。., drives chronic inflammation, and directly injures the endothelium.²⁷ The question clinicians often ask is: how does smoking compare to lipid and biomarker risk?

INTERHEARTINTERHEART was a large international case-control study that compared risk factors in people who had had a first heart attack against matched controls across 52 countries. The article cites its finding that permanent general stress carried an odds ratio of 2.17 for myocardial infarction, with psychosocial factors together accounting for a population-attributable risk of roughly 32.5%. provides one of the most useful comparisons because it included diverse populations across 52 countries.⁵ It showed that current smoking had one of the highest individual odds ratios for MI, but 脂質異常症Dyslipidemia is the medical word for an unhealthy pattern of fats in the blood. It can mean high LDL, high triglycerides, low HDL, or some combination. (measured by ApoB/ApoA1 ratioA lipid risk metric comparing the concentration of ApoB (reflecting all atherogenic particles) to ApoA1 (reflecting HDL, the primary reverse-cholesterol-transport particle); used in INTERHEART as a proxy for dyslipidemia, it had an odds ratio of 3.43 for myocardial infarction and the highest population attributable risk of any single risk factor studied.) carried an even larger population attributable risk, because dyslipidemia is so common globally.²⁸

リスク要因危険因子とは、高コレステロール粒子、高血圧、喫煙、糖尿病、家族歴など、病気にかかる可能性を高めるものです。.	Odds Ratio (OR)An odds ratio is a statistical measure expressing how much more (or less) likely an outcome is in one group compared with another; an OR of 1.71 for ApoB and coronary heart disease means that genetically higher ApoB is associated with 71% higher odds of developing the disease. for MI	Population Attributable Risk (PAR)
Current Smoking	3.63	35.7% (Global)
High ApoB/ApoA1 Ratio	3.43	54.1% (Global)
Diabetes Mellitus	3.42	16.4%
高血圧Hypertension is the medical term for high blood pressure.	1.89	10.7%

The Female Paradox: Sex-Specific Risk Sensitivities

Large cohorts show that women may experience a greater relative increase in MI risk from certain exposures, especially smoking and metabolic dysfunction.²⁹ In UK Biobank, current smoking was linked to a ハザード比ハザード比は、2つのグループでイベントが起こる速さを比較するものです。比率が0.75の場合、治療群でのイベント発生率が4分の一減少し、対照群の4分の3であったことを意味します。. for MI of 3.46 in women compared with 2.23 in men, producing a ratio of hazard ratios (RHR)A comparison of the hazard ratio for a given exposure (such as smoking) in one group (women) versus another (men), used to quantify sex-specific differences in risk; an RHR greater than 1.0 indicates the exposure is relatively more harmful in the first group. of 1.55.²⁹

Clinical Implications: Managing the Residual Risk Triad

Even with excellent statin therapy and strong LDL-C lowering, cardiovascular events still occur. This is often referred to as 残留リスクResidual risk is the risk that remains after you have done the obvious things — cholesterol treated, blood pressure controlled, not smoking., and it commonly reflects a combination of residual particle risk (ApoB), genetic risk (Lp(a)), and 残存炎症リスクResidual inflammatory risk refers to the persistent elevation of cardiovascular event rates in patients who have already achieved guideline-recommended LDL-C targets but continue to have elevated inflammatory markers such as hsCRP; it represents a second, parallel pathway of atherogenesis that lipid-lowering alone does not address. (hsCRP).³⁰

Statins lower LDL-C and reduce events, but they have little effect on Lp(a), and multiple studies suggest statins may increase Lp(a) modestly (often ~10–20%).³¹ PCSK9阻害薬A PCSK9 inhibitor is a medicine that blocks that cholesterol-destroying protein, leaving more docking ports available to clear particles from the blood. reduce LDL-C substantially and also lower Lp(a) by about ~27%.³²

The most promising future approach is direct Lp(a) lowering using antisense oligonucleotides (ASOs) or siRNA platforms, which have shown 80–90% reductions in early studies.³³ Finally, inflammation-focused trials such as カントスCANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) was a large randomized trial that tested canakinumab, a drug blocking the inflammatory signal IL-1β, against placebo; at its prespecified 150 mg dose it reduced major cardiovascular events by roughly 15% without lowering LDL cholesterol, providing direct human evidence that inflammation drives heart attacks through a pathway indepen… demonstrated that reducing inflammatory signaling (independent of lipids) can reduce MACE, reinforcing the clinical reality that inflammation is not just a bystander.³⁴

Conclusion: The Integrated Risk Map

Preventive cardiology is increasingly moving from a single-marker “cholesterol hypothesis” toward a more integrated approach. In practical terms, ApoB tells you particle burden, Lp(a) tells you inherited atherothrombotic risk, and hsCRP tells you about inflammatory activation. When these risks cluster, events can occur despite “good” LDL-C numbers.

Used together, these markers support more individualized decisions about therapy intensity and emerging targeted treatments—aimed at achieving the deepest possible reduction in cardiovascular risk.

参考文献

1. Nicholls SJ, Nelson AJ. Current perspectives on Lp(a)-lowering therapies: Who may benefit?. Kardiol Pol. 2025;83(6):688-694. doi:10.33963/v.phj.106327
2. Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69(6):692-711. doi:10.1016/j.jacc.2016.11.042
3. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103(13):1813-1818. doi:10.1161/01.cir.103.13.1813
4. Markus MRP, Ittermann T, Mariño Coronado J, et al. Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events. Eur Heart J. 2025;46(39):3863-3874. doi:10.1093/eurheartj/ehaf281
5. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-952. doi:10.1016/S0140-6736(04)17018-9
6. Sniderman AD, Navar AM, Thanassoulis G. Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk: The Debate Is Over. JAMA Cardiol. 2022;7(3):257-258. doi:10.1001/jamacardio.2021.5080
7. Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2009;55(3):407-419. doi:10.1373/clinchem.2008.118356
8. Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol. 2021;37(8):1129-1150. doi:10.1016/j.cjca.2021.03.016
9. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5(2):105-113. doi:10.1016/j.jacl.2011.02.001
10. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116(16):1832-1844. doi:10.1161/CIRCULATIONAHA.106.676890
11. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014;34(3):509-515. doi:10.1161/ATVBAHA.113.300156
12. Borén J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol. 2016;27(5):473-483. doi:10.1097/MOL.0000000000000330
13. Miller YI, Choi SH, Wiesner P, et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res. 2011;108(2):235-248. doi:10.1161/CIRCRESAHA.110.223875
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
15. Albers JJ, Marcovina SM. Standardization of apolipoprotein B and A-I measurements. Clin Chem. 1989;35(7):1357-1361.
16. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008;117(2):176-184. doi:10.1161/CIRCULATIONAHA.107.715698
17. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90(1):52-60. doi:10.1172/JCI115855
18. Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86(6):607-614. doi:10.1007/BF00201550
19. Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol. 2004;15(2):167-174. doi:10.1097/00041433-200404000-00009
20. Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008;49(10):2230-2239. doi:10.1194/jlr.M800174-JLR200
21. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330(6144):132-137. doi:10.1038/330132a0
22. Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem. 2004;37(5):333-343. doi:10.1016/j.clinbiochem.2003.12.007
23. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868-874. doi:10.1038/nature01323
24. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357-1361. doi:10.1038/nature08938
25. Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circ Res. 2016;118(1):145-156. doi:10.1161/CIRCRESAHA.115.306656
26. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. doi:10.1056/NEJMoa0807646
27. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43(10):1731-1737. doi:10.1016/j.jacc.2003.12.047
28. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372(9634):224-233. doi:10.1016/S0140-6736(08)61076-4
29. Millett ERC, Peters SAE, Woodward M. Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants. BMJ. 2018;363:k4247. Published 2018 Nov 7. doi:10.1136/bmj.k4247
30. Ridker PM. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J. 2016;37(22):1720-1722. doi:10.1093/eurheartj/ehw024
31. Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(24):2275-2284. doi:10.1093/eurheartj/ehz310
32. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664
33. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med. 2020;382(3):244-255. doi:10.1056/NEJMoa1905239
34. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914